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Ketamine, via intravenous infusions, has emerged as a novel therapy for treatment-resistant
depression, given rapid onset and demonstrable efficacy in both unipolar and bipolar
depression. Duration of benefit, on the order of days, varies between these subtypes, but
appears longer in unipolar depression. A unique property is reduction in suicidality although
data are more limited. Strategies to extend duration, via multiple doses, maintenance
treatment, or subsequent augmenting medications have yielded mixed results. There is a
relative paucity of data regarding alternate methods of administration such as intramuscular,
intranasal, and oral routes, though preliminary results are promising. Adverse effects most
reliably incl ude dissociative and sympathomimetic effects, both transient and mild, and
suggest good tolerability. Ketamine's unique effects may represent an opportunity for a
paradigm shift in the pharmacologic treatment of depression.
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espite significant progress, depression remains
a common and disabling condition that affects
millions, leading to increased primary care
visits and decreased productivity (Baune, Adrian, &
Jacobi, 2007). Both psychotherapy and antidepressant
pharmacotherapy are evidence-based treatments
recommended by experts and treatment guidelines
(Gelenberg et al., 2010). For those with more severe
depression, pharmacotherapy is often required for
recovery. However, inadequate response and lack of
remission are common, and characterize treatmentresistant depression (TRD; Keitner and Mansfield,
2012). The current pharmacopoeia available to clinicians
is primarily based on modulation of serotonergic,
noradrenergic, and dopaminergic transmission in the brain,
with first line agents primarily consisting of selective serotonin reuptake inhibitors (SSRIs; Keitner & Mansfield,
2012). As demonstrated by the STAR*D study, multiple
trials of medications are frequently required to achieve
remission, and despite this, about 35% of patients remain
symptomatic after several successive interventions (Rush
et al., 2006; Olin, Jayewardene, Bunker, & Moreno,
2012). When monoamine modulating antidepressant
medications do work, there is typically a delay of weeks
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before response is achieved. In those first few weeks,
antidepressant treatment may increase risk of suicidal
behavior, and possibly including completed suicide
(Björkenstam et al., 2013). With the lack of rapid
response from existing medications, and indeed the
apparent risk until such response, there is urgent need
for development of rapid acting treatment alternatives
for depression (Monteggia, Gideons, & Kavalali, 2013).
For severe depression, electroconvulsive therapy (ECT)
is the only somatic intervention with the potential for
more rapid treatment effect, however concern over
adverse effects limit use. Alternative approaches utilizing
direct electrical modulation, including repetitive
transcranial magnetic stimulation (rTMS), trigeminal
nerve stimulation, and deep brain stimulation (Cook,
Espinoza, & Leuchter, 2014) as well as magnetic seizure
therapy and vagal nerve stimulation (Wani, Trevino,
Marnell, & Husain, 2013) are promising in terms of
efficacy, but have not been shown consistently to have a
more rapid onset of effect than pharmacotherapy.
Studies suggest a role for the glutamate system
in regulation of mood (Skolnick et al., 1996; Matthews,
Henter, & Zarate, 2012; Machado-Vieira, Salvadore,
Diazgranados, & Zarate, 2009), and particular promise
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has been generated from studies looking at the N-methylD-aspartate (NMDA) receptor antagonist ketamine for
this novel indication (Artigas, 2013; Zarate et al., 2013;
Mathew, Manji, & Charney, 2008). Ketamine was
developed in 1963, first tested on humans in 1964, and
FDA approved for roles in anesthesia in 1970 (Reich et
al., 1989; JHP Pharmaceuticals, 2009). It was not until
2000 that ketamine was concretely demonstrated in the
literature to have antidepressant properties (Berman et
al., 2000). Ketamine has shown a large effect size, with
onset on the order of hours, and duration of effect of
approximately one week (Zarate et al., 2006). Reduction
in suicidal thoughts is further described, similarly within
hours of administration (Price et al., 2009; Price et al.,
2014).
A significant limitation exists in that ketamine
is only FDA-approved for intravenous (IV) or intramuscular (IM) use in induction or maintenance of
anesthesia, making administration in less controlled
settings difficult. While most studies on ketamine thus
far have looked at longer IV infusions, other routes have
shown promise for increasing patient access to ketamine
(Larkin & Beautrais, 2011; Harihar, Dasari, & Srinivas,
2013; Lara, Bisol, & Munari, 2013; Lapidus et al., 2014;
Iglewicz et al., 2014).
This article reviews the extant literature
regarding use of ketamine as an antidepressant,
highlighting its role as a rapid acting agent for unipolar
and bipolar depression. We report on and analyze efficacy,
with additional attention to durability of response,
improvement in suicidality, routes of administration,
dosing protocols, and safety. Different stereoisomeric
forms of ketamine are also reviewed given the possibility
that one form may be associated with fewer dissociative
effects. We conclude with recommendations for
future study design as well as potential off-label use
in less structured settings. Detailed discussions on the
history and neuropharmacology of ketamine, and the
glutamate theory of depression are not included; the
reader is referred to previous publications on these topics
(Domino et al., 2010; Krystal, Sanacora, & Duman,
2013; Caddy. Giaroli, White, Shergill, & Tracy, 2014;
Naughton, Clarke, Olivia, Cryan, & Dinan, 2014).
Materials and Methods
ubMed.gov was searched using the term “ketamine
depression,” with the filter of English language,
through March 2015, yielding 1042 studies. Studies
were excluded that did not investigate clinical use of
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ketamine in humans for treatment of depression, either
unipolar or bipolar, or suicidality. Those utilizing
ketamine as an anesthetic or augmenting agent for, or in
combination with, ECT or rTMS were excluded, as were
studies regarding the use of ketamine as an augmenting
agent for psychotherapy, for purposeful alteration of
consciousness, or in regards to ketamine misuse. The
remaining articles were further reviewed for pertinent
references. Data on depression response rates were
combined and recalculated to include intent to treat
(ITT) analysis, accounting for differences between rates
reported in the studies and in this review. To assess for
ongoing or planned studies a search of ClinicalTrials.gov
was performed with the terms “ketamine depression.”
Results
sing the above search criteria, a total of 61
publications from PubMed.gov and 96 from
ClinicalTrials.gov were identified for inclusion in this
review.
Study population and methodology
Of these 61 studies, 46 utilized the IV route
of administration, accounting for over 450 patients in
total. A further 18 studies utilized IM, oral, intranasal,
sublingual, or subcutaneous treatment in over 100
patients. Nearly all publications reported use of racemic
ketamine, with only 13 patients in total receiving
S-ketamine (Denk, Rewerts, Holsboer, ErhardtLehmann, & Turck, 2011; Paul, Schaaf, Padberg,
Moller, & Frodl, 2009; Segmiller et al., 2013; Paslakis,
Gilles, Meyer-Lindenberg, & Deuschle, 2010). Most
studies utilized only one administration of ketamine,
though five open label investigations (OLI) and one
randomized control trial (RCT) did assess multiple
doses, from one to three times per week, for up to three
weeks. The majority of publications reported on patients
with unipolar depression, though bipolar depression
was also represented in ten. Given the differences in
presentation, etiology, and response between these two
types of depression, these are considered separately. Save
for a minority of case studies (Table 5; Suppl. Table 1),
articles utilized one or more validated depression rating
scales, including the Montgomery-Åsberg Depression
Rating Scale (MADRS; Montgomery and Åsberg, 1979),
Hamilton Depression Rating Scale (HDRS; Hamilton,
1960), Beck Depression Inventory (BDI; Beck, Ward,
Mendelson, Mock, & Erbaugh, 1961), or Clinical
Global Impression scale (CGI; Guy et al., 1976). The
only study to report on the pediatric population utilized

U
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ratings scales more specific to that population (Papolos,
Teicher, Faedda, Murphy, & Mattis, 2013). Studies of
ketamine in hospice patients also utilized the Hospital
Anxiety and Depression Scale (HADS; Zigmond &
Snaith, 1983) (Table 5; Suppl. Table 1).
We focused on the categorical outcome of
response—defined as >50% reduction—within 24
hours since this was most commonly the primary
outcome measure referred to in the studies reviewed.
Remission was not consistently reported, and was also
variably defined. Notably, too, the majority of these
studies were performed in patients with treatment
resistance, and while definitions varied between studies,
this typically was qualified by at least two, if not more,
failed trials of adequate dose and duration antidepressant
treatment. Some also included failure of ECT and only
few described failure of adequate psychotherapy. To
objectively assess such trials, many studies utilized the
Antidepressant Treatment History Form (Sackeim,
2001). Unless otherwise specified below, we accept the
authors’ descriptions of TRD. Of the studies employing
ketamine IV infusions, most utilized racemic ketamine
0.5mg/kg over 40 minutes, with several more varying the
duration from 30 to 60 minutes. For the sake of brevity,
we abbreviate this protocol as KET in the rest of this
document.
Efficacy From Single Infusions
The eight RCTs investigating IV ketamine
included six crossover studies, all with saline placebo,
and two parallel group designs, both with active controls
(Table 1). All but one utilized a single ketamine infusion.
Six were done in patients with unipolar depression and
the other two in patients with bipolar depression. The
larger of the two active control and blinded RCTs utilized
midazolam and included 72 patients in a 2:1 ratio of
ketamine : midazolam, all with treatment-resistant
unipolar depression, who were discontinued from any
concomitant medications. In the ketamine group, 64%
responded at 24 hour follow-up, compared to 28% in
the midazolam group (Murrough, Perez, Mathew, &
Charney, 2013). Response rate in the ketamine arm
fell below 50% after day three. The other active control
blinded RCT utilized ECT as the comparison condition,
demonstrating a more rapid onset of action and greater
response rates at 24 hours in the ketamine arm; KET
elicited 78% response versus 11% with ECT (Ghasemi
et al., 2013). The other placebo controlled studies in
unipolar depression generally recruited fewer patients,
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and found 24 hours outcomes of 45% with KET versus
2% with saline; and 4 hour outcomes of 29% versus 7%
(Figure 1).
Both studies of patients with bipolar depression
were performed by the same group and found more
rapid onset, but shorter duration, of benefit (Table 1).
Response was 58% in the first four hours, but by day
one, half of the cohort no longer met this criterion
(Figure 2). While studies in unipolar depression generally
discontinued psychotropic medications and provided a
washout period, those in bipolar depression maintained
patients on therapeutic levels of mood stabilizers, either
lithium or valproic acid, which may have had an effect
on outcome.
Limitations in blinding and control selection
are prevalent in all but Murrough et al. (2013), who
utilized midazolam as an active control. The trial with
ECT as the active control (Ghasemi et al., 2013) did
not appear to have had strict patient blinding, despite
blinding of the treatment team. Valentine et al. (2011)
was the opposite, with study personnel being aware
of experimental conditions. Other studies utilized a
saline placebo, but the apparent ease in recognition of
dissociative effects likely sabotaged the blind.
Seventeen OLIs describe outcomes in unique
depressed patients after KET, of which sixteen were
principally in unipolar depression (Table 2). Nearly half
of the over 250 unipolar depression patients, 95% of
whom were categorized as TRD, responded within 4-6
hours after KET (Figure 3). At 24 hours, the overall
response rate increased to 59% and then gradually
declined with time. While 4 week outcomes were only
available for 47 individuals, the 21% response rate after
a single infusion is remarkable in light of the high degree
of treatment resistance. Each open-label trial was focused
on some aspect of KET besides acute antidepressant
efficacy per se, with several valuable findings. Thakurta
et al. (2012) demonstrated robust, but short-lived (< 3
days) antidepressant effects of standard dose KET in an
Indian population. Ibrahim et al. (2011) demonstrated
that a history of non-response to ECT was not
associated with a reduced likelihood of response to KET
in TRD. Machado-Vieira et al. (2009) did not detect
change in peripheral blood brain-derived neurotrophic
factor (BDNF) levels or correlation between BDNF
and MADRS scores, in 23 TRD subjects over the
first 4 hours after KET. Salvadore et al. demonstrated
correlations between short-term antidepressant response
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to KET and pretreatment signals in prefrontal cortex
on magnetoenchephalography (2009, 2010) and proton
magnetic resonance spectroscopy (2012). In support of
this possibility, Cornwell et al. (2012) demonstrated

that stimulus-evoked somatosensory cortical magnetoencephalographic responses were increased after
ketamine infusion in responders, but not non-responders
to KET. Phelps et al. (2009) identified another link to

Figure 1. Randomized, crossover, controlled trials, response rates in unipolar depression
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Figure 2. Randomized, crossover, controlled trials, response rates in bipolar depression
100%
90%
80%
70%
60%

10/17

18/31

50%

14/31

13/31

40%
30%

ketamine

10/31

10/35

saline

5/31

20%
10%
0%

0/28

0/28

0/28

40min - 4hr

1 day

2 days

2/31

1/28

0/28
3 days

7 days

1/28

10 days

2/31
0/28
14 days

Figure 3. Open Label IV ketamine, response rates in unipolar depression
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a potential biomarker, demonstrating that non-alcoholdependent MDD subjects with a family history of
alcoholism had a substantially greater likelihood of
response to KET than those without. Luckenbaugh
et al. (2012) reported similar findings from a posthoc analysis of RCT data (Diazgranados et al., 2010a;
Zarate et al., 2012). Both Mathew et al. (2010) and
Ibrahim et al. (2012) failed to demonstrate benefits from
randomization to riluzole over placebo during planned
month-long follow-up treatment after response to openlabel KET. Finally, Larkin and Beautrais (2011) found
administration of a lower total ketamine dose (0.2 mg/
kg), via IV bolus rather than slow infusion, permitted
use in an emergency department setting by busy
clinicians. While they reported cumulative remission
of 71.4% in the first four hours, improved response
in the subsequent two weeks must be interpreted in
light of telephone follow up and naturalistic treatment,
including inpatient care (this data omitted from the
table).
The one OLI solely in patients with treatmentresistant bipolar depression demonstrated progressive
decreases in mean HDRS score and increases in response
(Rybakowski, Permoda-Osip, Skibinska, Adamski, &
Bartkowska-Sniatkowska, 2013; Table 2). Response
more than doubled from 24% at 1 day to 52% at 1 week,
remaining stable for the duration of the two week long
trial. Patients were maintained on a variety of mood
stabilizing medications, although a limitation of the
study is that subjects were tapered off of antidepressants
as recently as 2 weeks prior to KET. This may potentially
explain the large disparity in outcome data from the
more rigorously designed RCTs.

Multidose Studies
One RCT and five OLIs assessed multiple
sequential doses of IV ketamine (Table 3). Of these,
three utilized a regimen of thrice weekly infusions for
two weeks. Another utilized up to four infusions, at a rate
of two per week over two weeks, stopping once patients
achieved remission. Only one study directly compared
two different schedules: once weekly versus twice weekly
infusions over the course of three weeks (Diamond et
al., 2014). All six noted either stable or increasing rates
of response over subsequent infusions. The response rate
for all subjects within 24 hours of their final infusion
was 59%, though if the outlier is excluded (Diamond
et al. 2014), this increases to 74%. The majority of
these studies also reported time to relapse after the final
infusion, monitoring subjects over the subsequent 4
weeks or longer, however criteria for relapse varied from
liberal (aan het Rot et al., 2010) to conservative (Shiroma
et al., 2014). Summing totals from these studies over
each time point reveals 50% of patients no longer met
response criteria between 7-10 days following the final
infusion, which may potentially underestimate true
benefit due to our conservative calculations (Figure 4).
The one RCT compared three ketamine
infusions with three bilateral ECT treatments over one
week, finding 89% response rate after three ketamine
infusions versus 67% with ECT (Ghasemi et al.,
2013). Regarding the five OLIs, all unique patients are
represented in Murrough et al. (2013), Rasmussen et
al. (2013), Shiroma et al. (2014), and Diamond et al.
(2014). Response rates immediately after conclusion of
the series of infusions were 71%, 60%, 79%, and 29%,
respectively (ITT). Diamond et al. (2014) was again

Figure 4. Open label and RCT mutidose infusion, response rates in unipolar depression
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(65%)

*

10/21
(48%)

1
days

*

36/69
36/69
(52%)
(52%)

*

14/22
(64%)

14/26
(54%)

8/21
(38%)

*

33/78
(42%)

4/9
(44%)

7/22
(32%)

14/26
(54%)

8/21
(38%)

13/25
(52%)

22/69
22/69
(32%)
(32%)

3/22
(14%)

14/26
(54%)

5/21
(24%)

2
3
7
days days days

*

18/47
(38%)

*

14/26
(54%)

4/21
(19%)

13/25
(52%)

17/69
17/69
(25%)
(25%)

1/22
(5%)

12/26
(46%)

4/21
(19%)

11/47
11/47
(23%)
(23%)

8/26
(31%)

3/21
(14%)

10
14
21
days days days

10/
10/47
(21%)
(21%)

7/26
(27%)

3/21
(14%)

28
days

				
																			
																			

* some studies did not report depression response at all time points.
[1][3][4] Studies with overlapping patients.
[7] Subjects overlap with Thakurta et al. 2012.
[2] Responders were randomized to daily riluzole or placebo, but upon subsequent analysis differences determined to non-significant.
All studies utilized a single 0.5mg/kg IV infusion over 40 minutes except [11] over 45 minutes, [6] 0.2mg/kg IV over
[5] Subjects randomized to pretreatment with one time dose of either lamotrigine 300 mg or placebo, to assay if this would attenuate
1-2 minutes, [9] 1-4 such IV infusions over 100 minutes; 2x/wk for 2wks or remission, [8] 6 infusions; 3x/wk for 2 wks.
dissociative effects and improve antidepressant benefit. No significant effect was found. Relapse criteria was defined as MADRS≥20
[10] Calculation excluded Cornwall et al. 2012 and Ibrahim et al. 2012 due to preponderance of non-unique subjects.
and MADRS increased by 10 from day 3 score, both for two consecutive visits.						

yes

36

47

54

47

48

50

31

48

50

51

44

47

46

47

44

44

Age

1/25
(4%)

2013

bipolar

3M/6F

16M/12F

14M

4M/6F

15M/9F

10M/12F

7M/7F

16M/10F

9M/5F

?

7M/4F

26M/16F

15M/5F

24M/18F

14M/12F

14M/9F

Gender

Rybakowski
et al. [11]

9

28

14

10

24
14 unique [4]

22
[7]

14

26
[4]

14
10 unique [3]

15
8 unique [3]

11
[3]

42
2 unique [1]

20,
0 unique [1]

42
[1]

26
[1]

23
[1]

N

124/278
124/278
(45%)
(45%)

yes

yes

yes

yes

yes

yes

no

yes

yes

yes

yes

yes

yes

yes

yes

yes

TRD

Totalsfor
forUnipolar
Unipolaror
orMixed
Mixed
Totals
%responding
responding[10]
[10]
%

unipolar

unipolar (22)
bipolar (6)

unipolar

unipolar,
bipolar II

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

Year Diagnosis

Study

Table 2. Open label investigations of ketamine efficacy for depression

Unipolar or Mixed

Ryan, Marta, & Koek

Ketamine for Depression

2010

2013

2013

2014

2014

2013

aan het Rot
et al.

Murrough
et al.

Rasmussen
et al. [3]

Shiroma
et al.

Diamond
et al.

Ghasemi et
al. [4]

unipolar

unipolar
(22)
bipolar
(6)

unipolar

unipolar,
bipolar II

unipolar

unipolar

Diagnosis

yes

yes

yes

yes

yes

yes

TRD

18

13

15

14

10

24
14 unique
[1]

10
[1]

N

8M
10F

16M
12F

14M

4M
6F

15M
9F

5M
5F

Gender

38

47

52

47

48

51

Age

yes

yes

yes

yes

no
[2]

no

Concom
Meds

3; 3x/wk
for 1wk

6; 2x/wk
for 3wks

3; weekly
for 3wks

6; 3x/wk
for 2wks

1-4; 2x/
wk for
2wks or
remission

6; 3x/wk
for 2wks

6; 3x/wk
for 2wks

Doses

1wk of
infusions + 1
week

3wks of
infusions
+ 6 months

2wks of
infusions
+ 4wks

0-2wks of
infusions
+ 4wks

2wks of
infusions
+ 12wks

2wks of
infusions
+ 4wks

Interval

HDRS25
decr 50%

BDI
decr 50%

cumulative
MADRS
decr 50%

MADRS
decr 50%

MADRS
decr 50%

MADRS
decr 50%

Response
Measure

31/85
(36%)

7/9
(78%)

3/28
(11%)

3/28
(11%)

3/14
(21%)

2/10
(20%)

16/24
(67%)

9/10
(90%)

after 1st
infusion

21/47
(45%)

7/9
(78%)

3/13
(23%)

5/15
(33%)

*

6/10
(60%)

*

*

after 2nd
infusion

14/19
(74%)

8/9 (89%)

*

*

*

6/10
(60%)

*

*

after 3rd
infusion

50/85
50/85
(59%)
(59%)

8/9
(89%)

3/13
(23%)

5/15
(33%)

11/14
(79%)

6/10
(60%)

17/24
(71%)

9/10
(90%)

after final
infusion

33/61
33/61
(54%)
(54%)

9/9
(100%)

3/13
(23%)

5/15
(33%)

*

*

16/24
(67%)

7/10
(70%)

3-4
days

31/85
31/85
(36%)
(36%)

9/9
(100%)

1/13
(8%)

5/15
(33%)

8/14
(57%)

5/10
(50%)

15/24
(63%)

5/10
(50%)

6-7
days

15/52
15/52
(29%)
(29%)

1/13
(8%)

4/15
(27%)

*

*

10/24
(42%)

5/10
(50%)

10-11
days

25/76
25/76
(33%)
(33%)

1/13
(8%)

4/15
(27%)

7/14
(50%)

3/10
(30%)

10/24
(42%)

4/10
(40%)

14
days

12/52
12/52
(23%)
(23%)

1/13
(8%)

4/15
(27%)

*

*

7/24
(29%)

3/10
(30%)

17-18
days

21/76
21/76
(28%)
(28%)

1/13
(8%)

4/15
(27%)

7/14
(50%)

3/10
(30%)

6/24
(25%)

2/10
(20%)

20-21
days

10/52
10/52
(19%)
(19%)

1/13
(8%)

4/15
(27%)

*

*

5/24
(21%)

3/10
(30%)

24-25
days

17/76
17/76
(22%)
(22%)

f1/13
(8%)

4/15
(27%)

5/14
(36%)

3/10
(30%)

4/24
(17%)

2/10
(20%)

27-28
days

* some studies did not report depression response at all time points.31/85 (36%) Response data was recalculated conservatively, accounting for differences from published data. Data from first infusions are also
reported on tables 1 and 2 where appropriate.
[1] Patients overlap between studies.
[2] Three responders were started on venlafaxine as part of another study.
All studies utilized 0.5mg/kg IV over 40 minutes except [3] over 100 minutes, [4] over 45 minutes.											
[5] Calculation excluded aan het Rot et al. given these subjects are represented in Murrough et al.											
																			
																			
																			
								

RCT

Totals
Opel Label
Totals for
forOpen
Labeland
andRCT
RCT
%
% responding
responding [10]
[5]

Year

Study

Table 3. Multidose ketamine efficacy for depression

Open Label

the outlier. Altogether, studies yielded
a 22% response rate approximately a
month after conclusion of the course. In
Murrough et al. (2013), 17% remained
responders over an additional 3 months
follow-up, with only one receiving
other medication in the interim. These
authors also observed that initial nonresponders (at 4 hours after the first
infusion) were four times less likely
than initial responders to achieve
response at the end of 6 infusions.
Additionally, several studies noted that
patients required up to two infusions
before successfully achieving response
(Rasmussen et al., 2013; Diamond et
al., 2014), suggesting that one infusion
may be insufficient. Rasmussen et
al. (2013) added to the literature by
extending 0.5mg/kg infusions over 100
minutes (0.3 mg/kg/hr), the slower
rate permitting use without presence
of anesthesia personnel. Interestingly
enough, the study with the lowest
response rate was conducted in an ECT
recovery room and found that several
patients complained the setting was too
noisy, chaotic, or distressing (Diamond
et al., 2014). Also notable is that this is
the only study to use the BDI, a patient
rated scale, as an outcome measure.
The other study that was conducted in
an ECT recovery room had the next
lowest response rate (Rasmussen et al.,
2013). Diamond et al. (2014) is unique
in that they assessed memory at baseline
and after the treatment course, finding
improvements in autobiographical,
episodic, and subjective memory. This
study was also the only one to directly
compare different treatment regimens,
though unexpectedly found better
results with weekly versus twice weekly
infusions.
Case Reports
The 17 published case studies
(or judged equivalent) that utilized
KET comprised just over 30 patients
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and—save for one dose finding study and another
comparing racemic versus S-ketamine—typically utilized
multiple infusions (Suppl. Table 1). These reports on 1-3
patients describe dramatic improvement in depressive
symptoms and functioning in patients with TRD
(Kollmar, Markovic, Thuerauf, Schmitt, & Kornhuber,
2008; Liebrenz, Borgeat, Leisinger, & Stohler, 2007;
Liebrenz, Stohler, & Borgeat, 2009); antidepressant
effect of ketamine even when this was only arrived at
serendipitously (Ostroff, Gonzales, & Sanacora, 2005);
several descriptions of prolonged relief of depression
with repeated dosing (Correll, 2006; Messer et al.,
2010; Murrough et al., 2011); and safe use of ketamine
in depressed patients with severe medical comorbidities
or who were concomitantly treated with multiple other
CNS-acting medications (Kollmar et al., 2008; Liebrenz
et al., 2007, 2009; Stefanczyk-Sapieha, Oneschuk, &
Demas, 2008). There were notable examples of rapid
relief of intense dysphoria and crying in a terminally
ill cancer patient on a palliative care unit (StefanczykSapieha et al., 2008). The cases of Yang, Zhou, Gao, Shi,
and Yang (2013) demonstrated rapid relief of depression
in young, drug-naïve men. Szymkowicz, Finnegan, and
Dale (2013) administered between 16-34 repeated KET
infusions to three TRD patients over a 12 month period,
adjusting frequency depending on individual response.
Their first patient remitted after the 2nd infusion, and
was maintained so with periodic treatments over the
subsequent 9 months. Their two other subjects suffered
repeated relapses despite intermittent courses of repeat
infusions. Lai et al. (2014) is unique in that it is the
only dose finding study, comparing 0.1 to 0.4mg/kg of
ketamine IV over 5 minutes and a saline control, but due
to low enrollment and poor retention, was placed with the
cases. Only one of the four individuals displayed a clear
dose response relationship for antidepressant response,
though dissociative effects were clearly dose related.
Alternate Routes of Administration
In contrast to most studies of IV infusion,
studies into intramuscular, subcutaneous, intranasal,
oral, and sublingual dosing have mostly utilized multiple
administrations attempting to extend response (Table
5). Bioavailability of these different formulations ranges
from ~20% for oral, ~30% for sublingual, 45% for
intranasal, to 93% for intramuscular (Clements, Nimmo,
& Grant, 1982). Dose, frequency, follow up interval,
treatment setting, and response metrics varied greatly
between publications. All patients had their existing
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medications continued, potentially biasing results.
Onset of benefit was generally rapid in parenteral routes,
and was successfully maintained with repeat dosing in
several instances.
In regards to IM administration, one OLI and
five case studies detailed effects in 25 patients. The
OLI study (Chilukuri et al., 2014) was notable in that
it directly compared outcomes from different routes of
administration (0.5mg/kg IV over 40 minutes, 0.25mg/
kg IM, and 0.5mg/kg IM) and found comparable
response rates of 33-44% immediately and several days
after administration. In contrast, in the case reports,
doses ranged from 0.5mg/kg to 1.0mg/kg, from every
3-8 days, and from 2-68 treatments. The five patients
with unipolar depression all met formal criteria for
response by 24 hours. Glue, Gulati, Le Nedelec, and
Duffull (2011) also performed a dose-response assessment
finding greater improvements with higher doses; while
0.5mg/kg and 0.7mg/kg decreased MADRS scores, only
1.0mg/kg led to response. Zanicotti, Perez, and Glue
(2012, 2013) described a woman with metastatic cancer
and unipolar TRD who, after 1.0mg/kg, experienced
remission of depression for 5-6 days, and pain for 24
hours. On a weekly outpatient regimen, response was
largely maintained for 8 months. Two patients with
bipolar depression experienced qualitative improvement
within days to a week after 0.5mg/kg or 0.9mg/kg IM,
that was maintained for 9-12 months by dosing at 3-4
day intervals, although one patient did require a dose
increase after five months (Cusin, Hilton, Nierenberg,
& Fava, 2012).
Three studies utilized intranasal administration,
of which one was a double blinded crossover RCT that
compared ketamine 50mg with saline (Lapidus et
al., 2014). This study found significant differences in
MADRS through two days, and a response rate of 44%
at 24 hours, comparable to other RCTs that utilized
ketamine infusions (Table 1; Figure 1). The second trial
was a case series of 12 pediatric subjects (ages 6-19) with
bipolar TRD that received a dose between 30-120mg.
Onset of benefit was frequently within the hour, lasting
for 3-4 days, and maintained for months with once to
twice weekly dosing (Papolos et al., 2013). The final case
describes successful long term maintenance of euthymia
with twice weekly intranasal administration.
The one study on sublingual administration,
in a mixed cohort of unipolar and bipolar depression,
utilized a 10mg dose and found “rapid” improvements
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Ketamine for Depression

Open Label Trials

unipolar (22)
bipolar (6)

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

unipolar

bipolar I and II

bipolar I and II

unipolar

unipolar (8)
bipolar (1)

Diagnosis

yes

yes

yes

yes

yes

no

yes

yes

yes

yes

yes

yes

yes

no

TRD

28

10

24
14 unique
[5]

42
2 unique
[3]

27
[2]

14

33
[3]

10
[5]

26
0 unique
[5]

57
0 unique
[1]

15

18

18

9

N

16M/12F

4M/6F

15M/9F

26M/16F

13M/14F

7M/7F

20M/13F

5M/5F

16M/10F

27M/30F

7M/8F

6M/12F

6M/12F

4M/5F

Gender

47

47

48

47

49

31

46

51

48

47

47

48

47

37

Age

yes

yes

no

no
[4]

no

yes

no

no

no

no

yes

yes

no

no

Concom
Meds

1-2x/wk
for 3wks

1-4; 2x/wk
for 2wks

6; 3x/wk
for 2wks

1

1

1

1

6; 3x/wk
for 2wks

1

1

1

1

1

1

Number of
infusions

3 wks of
infusions
+ 6 months

0-2 wks
infusions
+ 4wks [7]

2 wks of
infusions
+ 12wks [6]

28 days

2 days

10 days

230 minutes

2 wks of
infusions
+ 4 wks [6]

24 hours

7 days

14 days

14 days

7 days

72 hours

Interval

HAMD-SI
group mean

SSI group
mean

MADRS-SI
group mean

SSI group
mean

SSI group
mean

MADRS-SI
group mean

SSI < 4

MADRS-SI <=1

MADRS-SI <=1

SSI < 4

MADRS-SI
group mean

MADRS-SI
group mean

HDRS-SI group
mean

HDRS-SI group
mean

Response
Measure

2.0 (SD=0.9)

3.7±1.95

*

2.55

4.85 ± 5.37

3.9 (0.4)

23/33
(70%)

2/10
(20%)

7/26
(27%)

27/57
(47%)

2.3

*

*

*

Baseline

*

*

1.9±0.66
(p < 0.01)

0.78±1.48
(p = 0.001)

0.6 (0.1)
("significantly
lower than
baseline")

32/33 (97%)

*

*

*

0.25
(vs. 2.2 with
saline,
p < 0.001)

*

*

40mn6hr

0.7 (SD=1.1)

1.6±1.65
(p=0.007)

*

no significant
changes
throughout
study

~3.5
(p > 0.05)

*

9/10
(90%)

21/26
(81%)

86%
(vs. 62% with
midazolam,
p = 0.04)

1.1
(vs. 2.2 with
saline,
p < 0.01)

not significant
for any time
point

"significant
effect" for
ketamine

*

1
days

*

*

*

4.41±4.8
(p = 0.53)

*

*

*

1.1
(vs. 2.1 with
saline,
p < 0.01)

*

*

2
days

*

*

*

*

*

*

1.3
(vs. 2.3 with
saline,
p < 0.01)

*

"significantly
decreased"
(p = 0.02)

3
days

**some studies did not report depression response at all time points.
Suicidality was assessed as a secondary or post-hoc measure; trials were designed to assess response rates for depression as the primary outcome measure.
[1] Patients overlap with Murrough et al. 2013.													
[2] Patients overlap with Thakurta et al. 2012.						
[5] Patients overlap between studies.		
[3] Patients overlap between these studies.								
[6] Data reported is for after completion of first infusion.		
[4] Responders were randomized to riluzole or placebo, but upon analysis differences found to non-significant.		
[7] Data reported is for after completion of all infusions.				
			

2014

2011

Larkin and
Beautrais

Diamond et al.

2010

DiazGranados
et al.

2013

2010

aan het Rot et al.

Rasmussen
et al.

2009

Price et.al.

2013

2014

Price et.al.

Murrough et al.

2012

Zarate et al.

2012

2010

DiazGranados
et al.

Ibrahim et al.

2006

Zarate et al.

2012

2000

Berman et al.

Thakurta et al.

Year

Study

Table 4. Suicidality

RCTs
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Intramuscular

50

Intranasal
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Sublingual Subcutaneous O/S*

case
series

case
series

Irwin et al.

Iglewicz
et al.

case
series

Paslakis
et al.

case
series

case

McNulty
et al.

De Gioannis
and Leo

case

Gálvez
et al.

open
label

case
series

Lara et al.

Irwin et al.

RCT,
crossover

Lapidus
et al.

case
series

Papolos
et al.

case

open
label

Chilukuri
et al.

Clark

case
series

Cusin et al

case
series

case
series
case

Glue et al.

Zanicotti
et al.
[1]
Harihar
et al.

Type

Study

2014

2014

2013

2010

2010

2012

2014

2013

2014

2014

2013

2014

2012

2013

2012,
2013

2011

Year

unspecified
depression

bipolar, SI

unipolar

unipolar

unipolar

unipolar

unipolar,
melancholic

unipolar (12),
bipolar (14)

unipolar

bipolar I,
Fear of Harm
phenotype
unipolar

unipolar

bipolar II

unipolar

unipolar

unipolar

Diagnosis

no

yes

no

no

no

yes

yes

yes

yes

yes

yes

yes

yes

unclear

yes

yes

TRD

31
[3]

14
12 unique
[3]
2

2
[3]

4

1

1

26

20

1

11M
20F

1F
1M

?/1M/7F

1M/1F

?/1M/2F

1M

1F

8M/18F

10M/10F

1F

2M/7F
10M/2F

9
12

68

37
44

?

64,70

36-57

44

62

22-83

48

44

42
6 - 19

32

48

1F
1M/8F

57

21

23

36

?

Age

1F

1M

1M

1F

2F

Gender

9

2

2

1

2

N

hospice

none
chronic pain

hospice

melancholia,
AvPD†
alcohol abuse
hospice: COPD,
neoplasia

hospice

HTN, hypothyroid, CVA

various

none reported

migraines

n/a
unclear

ADHD,
fibromyalgia,
hypothyroid
n/a

ADHD

metastatic
ovarian cancer,
pain
obsessive-compulsive disorder
none reported

none reported

Comorbidities

Table 5. Alternate routes of ketamine administration

0.5mg/kg

0.5-1.5mg/kg[4]
0.5-3.0mg/kg[4]

0.5mg/kg

0.5mg/kg

S-ketamine
1.25mg/kg

0.5mg/kg SC,
then daily [6]

0.1mg/kg, then
0.2mg/kg
0.2mg/kg [5]

1 - 12
[7]

6 or more
3 or more

28

12 to 14

up to three
times daily [7]

monthly
every 2-3 wks

nightly

once

split over three
times daily

daily

approx. weekly

12
many

a month apart

2

every 2-7 days

once

10 mg
(100 mg/mL)
for 5 minutes

once

twice weekly

once
every 3-7 days

once

every 3 days

every 4 days

every 3 days

every 3 days

every 7-8 days

unclear

Frequency

saline
1-90

32

many

61+

68+

2

2

7, 34

3

Number
of
doses

50mg

50mg

0.5mg/kg
30-120mg [2]

0.25mg/kg

50mg for 5mos,
then 70mg for
4mos (55kg)
50mg for 6 mos
(120kg)

0.5mg/kg

0.5mg/kg

0.5, 0.7, and
1.0mg/kg
1.0mg/kg

Dose ‡

21 days

>3 months
>4 months

28 days

several
months

14 days

11 weeks

9 months

9 months

up to
6 months

7 days

7 days

4 months

3 days
several
months

3 days

12 months

unclear, at
least 3 days
9 months

1 month

unclear, at
least 3 days
2 months,
8 months

Duration
of study

CGI

MADRS
MADRS

HDRS 17

HDRS 17

HDRS

clinical
assessment

MADRS

MADRS

custom 0-10
mood scale

MADRS

clinical
assessment
MADRS

HDRS
CBQ

HDRS

clinical
assessment

clinical
assessment

HDRS

HDRS

MADRS

MADRS

Outcome
measure

yes, 10/14 (71%)
[7]

yes
yes

yes, 1/2 (50%)
patients responded
by 120 min
no

no

yes, only at higher
dose
no, not until 3rd
treatment
yes

unclear, 17/26 (65%)
with "rapid" response

1/18 (6%)

yes, 8/18 (44%)

yes, 4/9 (44%)
yes, 12/12 (100%)
within 24hr, and
many within 1hr
no

yes, 3/9 (33%)

no

unclear

yes, remission at 2hr

yes, remission at 2hr

yes, 3/3 (100%), but
only at 1.0mg/kg
yes, remission at 1hr

Depression
response
within 24 hours

5/6 (83%) had response
start to fade at day 2-3 [7]

2/4 (50%) responded
at 7 days, maintained
through 14 days
1 month for initial
responder; other
responded at 8 days
unclear; mean time to
response 14.4±19.1 days
for 8/14 (57%) responders
unclear
unclear

11 weeks

10 weeks

5 months

20/26 (77%) had response
to at least one dose;
10/26 (38%) maintained
response for "months"

low throughout study

increased to 44%
at 3 days
3 days
"several months,",
72-96hrs of benefit after
each dose
"euthymic" by day 3,
maintained >4 months
3 days

remission "within a few
days", maintained for 9
months
responded "after 1 week,"
maintained for 6 months

remission after each
dose for 3-7 days, largely
maintained for 8 months
remission through
1 month
>3 days

not reported

Durability
of benefit
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*Oral and Subcutaneous. ‡ Doses administered are racemic ketamine unless otherwise noted. † Avoidant Personality Disorder.
All patients continued existing medications during treatment with ketamine.												
[1] Includes follow-up publication on the same patient.				
[5] Patient received a second course of treatment after initial relapse.				
[2] Variable dose: 100 mg/mL solution via metered nasal spray pump bottle.		
[6] An initial one time 0.5mg/kg (40 mg) subcutaneous dose was followed by 0.5mg/kg (40 mg) daily oral maintenance.
[3] Two patients overlap between these studies.				
[7] Of 31 subjects, 29 received ketamine orally, 1 received subcutaneous, and 1 received via both routes; 22 received
[4] Two patients received 0.5mg/kg orally, which was titrated up in 0.5mg/kg increments at
1 dose, 5 received 2 doses, and 4 received three times daily dosing for 3 days; time to first response and time to
follow-up sessions to final doses of 3.0mg/kg every 2-3 weeks and 1.5mg/kg monthly
fading of response available for smaller sample.							
													
															
																			
											

Oral

in 17 of the 26 patients, though the time frame was not
defined. Using repeat dosing, from every 2-7 days, ten
patients were described as maintaining response over a
period of months, based on a Likert scale (Lara et al.,
2013).
Subcutaneous administration has also been
reported on. McNulty et al. (2012) described a case of
“dramatic relief” from depression in a hospice patient
after initial subcutaneous administration of 0.5mg/
kg, followed by the same amount by mouth daily, with
maintenance for 11 weeks. Another case describes long
term maintenance of response with repeated doses,
notably at only 0.2mg/kg (Gálvez et al., 2014).
Oral, compared to parenteral, ketamine
administration results in a higher blood norketamine to
ketamine ratio because of extensive first pass metabolism.
Norketamine is pharmacologically active as an NMDA
antagonist and has analgesic and likely antidepressant
effects. It has longer elimination half-life than ketamine
itself. The clinical implications for treatment of depression
are unclear (Blonk, Koder, van den Bemt, & Huygen,
2010). We found four case studies and a subsequent
OLI that utilized oral administration. One case study
(Irwin & Iglewicz, 2010) in two hospice patients with
depression found response in both after a single dose of
0.5mg/kg, one within 120 minutes, the other at 8 days.
The follow-up OLI included 12 additional patients and
utilized daily dosing of 0.5mg/kg (Irwin et al., 2013),
finding 57% response rate, mean time to response of 14.4
days, and maintenance of response for at least 28 days.
Most recently the same authors published a retrospective
chart review involving 31 patients finding 71% response
at 24 hours after single oral doses of 0.5mg/kg (Iglewicz
et al. 2014). It is unclear why this study displayed such
rapid response, while the other did not. De Gioannis
and Leo (2014) described use of oral ketamine outside
the hospice setting, in two individuals with bipolar
disorder and suicidality, demonstrating maintenance of
response with escalating doses of oral ketamine every
two to four weeks.
S-Ketamine
Ketamine exists as a racemic mixture of the
S- and R- stereoisomers, and while most studies have
employed the racemate, a minority has solely used the
more potent S- stereoisomer. There may be differences
between the two, both in terms of antidepressant
response and dissociative effects, though results
are conflicting. Studies with S-ketamine describe

treatment in just over ten patients, all with unipolar
depression (Table 5, Suppl. Table 1). No reports utilizing
R-ketamine for treatment of depression exist. Only one
publication, a case report, describes direct comparison
between stereoisomeric forms of ketamine. Two patients
were each given equianalgesic IV infusions of racemic
ketamine 0.5mg/kg and S-ketamine 0.25mg/kg a
week apart (Paul et al., 2009). Robust antidepressant
response to both isoforms of ketamine was observed
in one patient, while the other responded to neither.
Further, both patients had mild dissociative/perceptual
disturbances (“psychotomimetic”) with the racemate
but not S-ketamine. Paslakis et al. (2010) treated four
individuals with S-ketamine using a total oral daily dose
of 1.25mg/kg, bioequivalent to 0.25mg/kg IV, divided
over three times daily and similarly found no dissociative
effects, and a 50% response rate. Conversely, subsequent
studies utilizing IV infusions of S-ketamine 0.25mg/kg,
either one time or multiple, found comparable response
rates soon after infusion, but did note strong dissociative
effects (Denk et al., 2011; Segmiller et al., 2013).
Suicidality
The data regarding reduction of suicidality with
ketamine is generally suggestive of benefit (Table 4). The
majority of studies did not assess suicidality as a primary
outcome measure, and also utilized group mean change
in suicidality scales rather than more easily interpretable
results such as percent of the cohort achieving lack of
suicidality. In regards to unipolar depression, three
RCTs and nine OLIs reported on suicidality, typically
utilizing either the HDRS or MADRS suicide items,
or the scale for suicide ideation (SSI; Beck, Kovacs, &
Weismann, 1979). Of these, only one OLI reported lack
of benefit. The others showed benefit at disparate time
points ranging from the first four hours post dose to three
days out. Time course data is present in only one study,
with loss of significance after four hours. Four studies,
however, reported categorical outcomes of percent of
subjects attaining an SSI or MADRS-SI score below
a certain threshold (resolution of suicidal thoughts).
These “response rates” ranged from 81% to 90% within
the first 24 hours. Another study found, at 4 hours, a
97% response rate in 33 previous ketamine responders,
and a 100% response among the high suicidality subcohort (Diazgranados et al., 2010b). Price et al. (2014)
reanalyzed data from the Murrough et al. (2013) RCT,
finding decreases in both explicit suicidality as well as
implicit associations (“Escape = Me”). Other case reports,

Ketamine for Depression

International Journal of Transpersonal Studies 51

Table 6. Ongoing and planned studies, Part 1. Randomized and double blind control studies
Sponsor

Date
initiated

Status

Study
design

Diagnosis

TRD

Primary Route
outcome

Ketamine
arm / dose

Placebo arm

Number of
doses

NIMH

2004, July

recruiting

parallel

MDD or
bipolar

yes

various

IV infusion / 40min

0.5mg/kg

unclear

unclear

Washington
University School
of Medicine

2010, August

recruiting

parallel

MDD

yes

HDRS

IV infusion / variable
duration

infusion over
100 hours

ketamine infusion
for 40 min, and
saline infusion
for 100 hours

single

The University of
New South Wales

2011, Sept

unknown

crossover

MDD or
bipolar

no

unspecified
depression
scales

IV, IM, and SC

variable 0.10.5mg/kg

saline or
midazolam

weekly
for 6 wks

Yale University

2012, March

recruiting

crossover

MDD or
bipolar II, and
alcohol dep.

no

HDRS

IV infusion / 40min

0.5mg/kg

saline

single

Columbia
University

2012, March

recruiting

parallel

MDD

no

HDRS

IV infusion / 40min

0.1, 0.2, 0.3, 0.4,
and 0.5mg/kg

saline

single

University Hospital,
Grenoble

2012, March

unknown

parallel

MDD

no

MADRS

IV infusion / 40min

0.5mg/kg + venlafaxine orally

Saline +
venlafaxine orally

single

Massachusetts
General Hospital

2012, May

enrolling by
invitation

parallel

MDD

yes

HDRS

IV infusion / 45min

0.25mg/kg

scopolamine
0.2ug/kg IV over
15 minutes

2x/wk
for 3 wks

Janssen Research
& Development

2012, June

completed
(unpublished)

parallel

MDD

yes

MADRS

IV infusion / 40min

0.5mg/kg / variable frequency
of doses

saline / variable
frequency of
doses

either 2x or
3x/wk
for 4 wks

Massachusetts
General Hospital

2012, August

ongoing, not
recruiting

parallel

MDD and SI

yes

HDRS

IV infusion

unclear dose

saline

2x/wk
for 3 wks

University of
Alabama at
Birmingham

2012, August

recruiting

parallel

SI

no

SSI

IV infusion

0.2mg/kg

saline

single

Mayo Clinic

2012, September

recruiting

parallel

Depression,
advanced
cancer

no

HADS-D,
HADS-A

oral

0.5mg/kg

unclear

single

New York State
Psychiatric Institute

2012, October

recruiting

parallel

MDD

no

unspecified
SI scale

IV infusion / 40min

0.5mg/kg

0.02mg/kg
midazolam

single

American British
Cowdray Medical
Center

2013, May

recruiting

parallel

MDD

yes

HDRS

IV infusion / 40min

0.5mg/kg

saline

single

University of
Ottawa

2013, May

recruiting

crossover

MDD

yes

HDRS

IV infusion / 40min

0.5mg/kg

midazolam

single versus
six infusions,
then weekly
for 3 wks

Mount Sinai School
of Medicine

2013, June

recruiting

parallel

MDD

yes

MADRS

IV infusion / 40min

ketamine +
lithium orally

ketamine +
placebo orally

unclear

Massachusetts
General Hospital

2013, August

recruiting

parallel

MDD

yes

HDRS

IV infusion

0.1, 0.2, 0.5,
and 1.0mg/kg

midazolam

single

New York State
Psychiatric Institute

2013, September

recruiting

parallel

bipolar

no

SSI

IV infusion / 40min

0.5mg/kg

midazolam

single

Janssen Research
& Development

2013, September

recruiting

parallel

MDD

yes

SEP, MEP;
unspecified
depression
scale

IV infusion / 40min

0.5mg/kg

unclear

single

New York
University

2013,
December

recruiting

parallel

MDD

no

MADRS

IV bolus

0.25mg/kg

diphenhydramine
25mg

single

Tel-Aviv Sourasky
Medical Center

2014, January

ongoing, not
recruiting

parallel

MDD or SA

yes

unspecified
SI measure

oral

ketamine

unclear

daily for 21
days

University of
Cincinnati

2014, July

not yet open

parallel

SI

no

MADRS,
SSI

intranasal

0.2mg/kg

saline

given in one
day over two
doses

Massachusetts
General Hospital

2014,
November

not yet open

parallel

MDD and SI,
age >65

yes

HDRS

intranasal

50mg

saline

2x/wk for 3
wks

Centre Hospitalier
Universitaire de
Nīmes

2014,
November

not yet open

parallel

SI

no

SSI

IV infusion / 40min

0.5mg/kg

saline

twice over 3
days

Minneapolis
Veterans Affairs

2015, Jan

not yet open

parallel

MDD

yes

MADRS

IV infusion / 40min

0.5mg/kg, 3x/wk
for 2wks

5 midazolam
infusions and 1
ketamine infusion

comparing
one versus 6
infusions
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utilizing IV infusions (Murrough et al., 2011; Zigman
& Blier 2013), and a case series with IM administration
(Harihar et al., 2013), all showed benefit. Conversely,
one OLI of oral ketamine in 14 hospice patients found
no such benefit (Irwin et al., 2013).
In bipolar depression, two RCTs and two case
series report on suicidality. The two RCTs, both by
the same group, conflict in finding significant benefit.
Zarate et al. (2012) demonstrated significant differences
in between-group MADRS-SI scores through three days.
Diazgranados et al. (2010a), on the other hand, found
no difference between IV ketamine and placebo, though
these authors excluded patients with risk for suicide at
baseline. One case series utilized IM administration and
showed qualitative improvement (Cusin et al., 2012),
while the other did so with oral doses every two to four
weeks (De Gioannis & Leo, 2014).
Adverse Effects
During infusion, two adverse events with
ketamine led to discontinuation in RCTs (Suppl. Table
2): hypotension and bradycardia, and hypertension
unresponsive to beta-blockers (Murrough et al.,
2013). Following infusion, four adverse events led to
discontinuation: worsening mood in three patients
(one with suicidal ideation), and increased anxiety in
the other (Diazgranados et al., 2010a). Two placebo

patients discontinued, one each during infusion and
after infusion for elevated blood pressure (Valentine et
al., 2011) and hypomania (Diazgranados et al., 2010a),
respectively. In OLIs, only two adverse events led to
treatment discontinuation out of nearly 300 individuals
(Suppl. Table 3): elevated blood pressure unresponsive
to beta-blockers during infusion (Murrough et al.,
2013), and a panic attack (Diamond et al., 2014). In case
reports, one subject receiving S-ketamine at 0.25mg/
kg discontinued during infusion due to dissociation
(Segmiller et al., 2013).
Tachycardia and transient elevations in blood
pressure were commonly reported hemodynamic effects
in RCTs and OLIs, though two cases of hypotension
(Murrough et al., 2013; aan het Rot et al., 2010), one
case of bradycardia (aan het Rot et al., 2010), and one
vasovagal episode were also reported. Aan het Rot et
al. (2010) also reported one patient with bradypnea,
with oxygen desaturation to 94%. To date, no RCTs or
OLIs have reported these effects persisting beyond four
hours, save for one patient with mild, asymptomatic
hypotension lasting until discharge at 24 hours (aan het
Rot et al., 2010).
Dissociation, psychotomimetic effects, manic
symptoms, and other psychiatric effects were assessed in
most investigations. In RCTs and OLIs adverse effects

Table 6. Ongoing and planned studies, Part 2. Open label studies
Sponsor

Date
initiated

Status

Study
design

Diagnosis

TRD Primary
outcome

Route

Ketamine
arm / dose

Number of
doses

University Hospital,
Geneva

2010, June

unknown

open label

MDD

yes

MADRS

IV infusion / 40min

0.5mg/kg

single

Massachusetts
General Hospital

2012, April

ongoing, not
recruiting

open label

MDD and SI

yes

HDRS

IV infusion / 45min

0.5mg/kg, then
0.75mg/kg for
nonresponders

2x/wk for 3 wks

Jinling Hospital,
Nanjing University
School of Medicine

2012, April

unknown

open label

MDD or bipolar

yes

MADRS, HDRS, SSI

IV infusion / 40min

0.5mg/kg

single

New York State Psychiatric Institute

2013, April

recruiting

open label

bipolar

yes

unclear

IV infusion / 60min

0.5mg/kg + d-cycloserine orally

single

Nationwide Children's Hospital

2013, August

recruiting

open label

SA, age 12-18

no

QIDS-C, CGI

IV infusion / 15min

0.5mg/kg

single

University of
Minnesota

2014, February

recruiting

open label

MDD, age 12-18

yes

CGI

IV infusion / 100min

0.5mg/kg

3x/wk for 2 weeks

Mayo Clinic

2014, March

recruiting

open label

MDD or bipolar,
and SI

yes

MADRS

IV infusion / 100min

0.5mg/kg

3x/wk for 2wks, then
weekly for 4wks

NIMH

2014, April

recruiting

open label,
parallel [1]

MDD

yes

MADRS

IV infusion / 40min

0.5mg/kg

single

UCLA

2014, June

recruiting

open label

MDD

yes

MADRS, HDRS

IV infusion / 40min

0.5mg/kg

single

Sheba Medical
Center

2014, August

not yet open

open label

MDD

yes

MADRS

IV infusion

0.5mg/kg

unclear

Yale University

2014,
November

not yet open

open label

MDD or bipolar

yes

Extinction Learning
Task performance

IV infusion

unclear

2x/wk for 2 wks, with
CBT for 8 wks

[1] Study will compare outcomes between those with and without family history of alcoholism.
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as measured by Clinician Administered Dissociative
Symptom Scale (CADSS; Bremner et al., 1998), Brief
Psychiatric Rating Scale (BPRS; Overall & Gorham,
1962) or Young Mania Rating Scale (YMRS; Young,
Biggs, Ziegler, & Meyer, 1978) revealed significant
increases compared with control/baseline, that generally
resolved by 80 min to four hours.
In the four OLIs utilizing repeat dosing, changes
in CADSS and BPRS were similar after each infusion,
with no progressive increase with multiple infusions.
Similarly, hemodynamic and respiratory effects did not
worsen with repeat administrations. Dose dependent
increases in dissociative symptoms were reported in one
ascending dose study, in which rapid IV infusions over
two to five minutes were used (Lai et al., 2014). Transient
tachycardia and asymptomatic premature ventricular
contractions were described in one patient, and nausea
and vomiting in another (aan het Rot et al., 2010;
Shiroma et al., 2014). One suicide attempt occurred
during the washout period before ketamine infusion
(Murrough et al., 2013). One report of mania was found
in a patient who received 34 doses of ketamine at variable
intervals over a 1 year period (Liebrenz et al., 2009), and
another reported a “mild” hypomanic episode in a patient
after his third infusion (Diamond et al., 2014). Niciu
et al. (2013) analyzed data from three NIMH RCTs
of IV ketamine infusion in bipolar depression, finding
transient increases in YMRS scores lasting no more than
a day after infusion, and no cases of full blown mania or
hypomania. They also reported that within the YMRS
elevations, none of the patients had specific elevations in
the elevated mood item (Suppl. Table 2).
Adverse effects in case reports were consistent
with those of RCTs and OLIs. Events uniquely described
in the case reports include the following: less pronounced
dissociation on a second dose compared to the first
(Liebrenz et al., 2009; Clark et al., 2014), hypomania
in one patient (Szymkowicz et al., 2013), “delirium”
for 5-8 minutes following 0.5mg/kg bolus (Yang et al.,
2013), and in a report of two patients, psychotomimetic
effects during racemic but not S-ketamine infusions
(Szymkowicz et al., 2013).
Intramuscular reports noted effects similar to
those of IV, without mention of hemodynamic changes.
In one case, decrease in dizziness and derealization
occurred over repeat (41 total) injections (Zanicotti
et al., 2013), whereas in another a dose of 1.0mg/kg
resulted in intolerable dissociative effects necessitating a
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dose decrease to 0.5mg/kg (Cusin et al., 2012). In one
intranasal study of 12 pediatric patients, transient (60
minutes) dissociative effects similar to IV were reported,
as well as mild palpitations and moderate respiratory
distress (Papolos et al., 2013), whereas in another
intranasal case report the patient described feeling
“high,” but only during the first few of more than thirty
administrations (Clark et al., 2014). Sublingual dosing
in 26 patients resulted in no euphoria, psychotic, or
dissociative symptoms. Lightheadedness (mild, transient,
and improving on repeat dosing) and one report of
tachycardia (<30 minutes) occurred. Mouth numbness
was the only novel effect reported (Lara et al., 2013). In
the 50 patients that received oral ketamine, essentially
no adverse effects, including vital sign changes, were
reported (Paslakis et al., 2010; Irwin & Iglewicz,
2010; Irwin et al., 2013), save for disorientation and
hallucinations in a minority of a medically ill hospice
population (Iglewicz et al., 2014). In fact, there were
improvements in BPRS and adverse symptom checklists
(Irwin & Iglewicz, 2010). Only diarrhea, trouble
sleeping, and “trouble sitting still” occurred (one each)
in a study of 14 patients (Irwin et al., 2013). The only
study of oral S-ketamine, divided over three times daily,
found essentially no side effects in all four patients.
Ongoing and Planned Studies
A review of ClinicalTrials.gov yielded five OLIs
and twenty RCTs (Table 6). Add-on oral medication
as a potential method for extension of benefit is being
investigated in a total of four studies: lithium, venlafaxine,
minocycline, and d-cycloserine. Multiple dose regimens
are being studied in nine trials, and suicidality is being
studied in five. Four are assaying escalating doses,
variable number of infusions, or increasing duration of
infusion. The majority utilize ketamine IV infusions,
while three are using intramuscular, intranasal, oral, or
subcutaneous methods of administration. In only one
study did we find a plan to include more than one route
of administration. All studies utilize racemic ketamine.
Discussion
iscussion is divided into consideration of antidepressant and antisuicidal effects, adverse effects,
ketamine's stereoisomers, further clinical issues, and
recommendations for future research.
Antidepressant and antisuicidal effects
Ketamine appears to have remarkably robust
efficacy in short-term relief of severe and treatmentresistant depression, with onset in hours, and duration

D
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of at least a few days. While this has been observed in
both unipolar and bipolar depressed populations, in
the latter, duration appears slightly shorter and there
are fewer supporting studies. Similarly, in cases of
non-TRD, this effect seems to hold, though relative
efficacy is unclear. Ketamine’s effectiveness in relief of
acute suicidal ideation is also a highly valuable finding,
though with less support. This benefit appears unique to
ketamine among available treatment options, although
comparisons with other active treatments are lacking.
Furthermore, there are conflicting findings as to whether
reductions in suicidality are specific, or rather related
to overall reductions in depression (Price et al., 2009;
Diazgranados et al., 2010b; Rasmussen et al., 2013;
Murrough et al., 2013). Studies for the most part have
excluded individuals with recent suicidality, and instead
performed post-hoc reanalyses of suicidality subscales,
though future studies are enrolling high risk individuals
for targeted therapy with ketamine (Table 6). To date
there are no data on suicide attempts, completed suicide,
or other long-term effects, nor on parasuicidal behavior.
Despite the limited amount of data, this is fertile ground
for further research given the great potential benefit
to treat emergent suicidality or avert hospitalization.
Ketamine deserves consideration for use in select patients
who otherwise would continue to suffer severely, if only
as a temporizing measure to give clinicians time to
identify and implement alternative treatments.
The largest challenge with this promising agent
remains the extension of benefit for the longer term,
which is pertinent to the vast majority of depressed
patients who have failed to benefit sufficiently from
psychotherapy, psychosocial interventions, and the
initial tiers of somatic intervention. Repeated ketamine
infusions have shown some promise, and there may
be a cumulative dose effect similar to ECT, where a
series of treatments are required to induce full response
or remission (aan het Rot et al., 2010; Murrough et
al., 2013; Rasmussen et al., 2013). Indeed, several
studies concluded patients require more than one
infusions before being considered non-responders. The
comparison to ECT is tempting, and certainly makes
for a good argument against those who would dismiss
the potential for ketamine in depression because of the
only short-term benefit of single infusions. It is far from
clear what the optimum dose, frequency, and number of
infusions will be, and how this might be individualized,
though future studies will be revealing. It also worth

noting that some patients do not benefit from ketamine,
despite multiple treatments (Szymkowicz, Finnegan, &
Dale, 2014).
Alternatives to IV infusion, such as intramuscular (IM), intranasal(IN), oral, sublingual (SL),
and subcutaneous (SC) routes, have been ástudied to a
lesser extent, but do appear to work, with the trade-off
of potentially lower response rates with all routes other
than the IM, which results in ketamine bioavailability
similar to IV administration. A significant limitation is
lack of high quality prospective studies: of these alternate
routes, our review found only one RCT, which utilized
IN administration (Lapidus et al., 2014). Compared with
IV administration, IM, IN, and SL routes are similarly
rapid acting, with conflicting and weaker data for SC and
oral administrations. Duration of benefit is similar to IV
infusions, on the order of days, but has been successfully
prolonged with repeated dosing, which is notably easier
given the relatively low resource requirements with such
administrations. Several cases describe treatment in an
office-based setting, with patients returning to the office
anywhere from multiple times a week to once a month,
and maintaining response on the order of months. It is
unclear if such response eventually fades, or rather if it
could be continued indefinitely, though several cases
describe maintenance for nearly a year (Zanicotti et al.,
2013; Cusin et al., 2012). Oral dosing, while used mostly
in hospice populations, appears to have slower onset of
benefit, though an initial loading dose via a rapid acting
route of administration could be combined with more
convenient maintenance daily oral administration, as in
one case report (McNulty et al., 2012).
Adverse effects
Ketamine appears to be well tolerated, the
most commonly reported adverse effects being transient
dissociative and psychotomimetic experiences. As noted
in several studies, patients appear to become tolerant to
such effects after several subsequent administrations,
and yet maintain a similar antidepressant response
(Berman et al., 2000; Paul et al., 2009; Luckenbaugh
et al., 2014). Occasionally, hemodynamic effects,
typically transient and mild, have led to treatment
discontinuation although in every case these have
responded to conservative management. There does not
appear to be a correlation between hemodynamic effects
and antidepressant response (Luckenbaugh et al., 2014).
In our review, sublingual, intranasal, and especially oral
administration generally resulted in fewer adverse effects
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than seen after IV administration, and may be due to a
slower increase in blood levels (Lara et al., 2013; Paslakis
et al., 2010; Irwin & Iglewicz, 2010; Irwin et al., 2013;
Iglewicz et al., 2014). Supporting this possibility, Lai et
al. (2014), found extensive dissociative symptoms with IV
administration over 2 minutes, leading them to mitigate
this issue by extending administration over five minutes.
The safety profile of short-term ketamine, particularly in
closely monitored settings, is reassuring.
There is however a relative paucity of data on
ketamine's adverse effects in the long-term treatment of
depression. Long-term exposure in abuse populations,
where dose and frequency far exceed those used in
clinical protocols, does suggest potentially serious
sequelae. In such populations, both short- and longterm neurocognitive adverse effects have been reported
(Curran & Monaghan, 2001; Morgan, Monaghan, &
Curran, 2004). Conversely, data from studies utilizing
ketamine for treatment of depression indicate that it
may actually improve neurocognitive outcomes, most
likely by reversing the “pseudo-dementia” seen in severe
depression (Permoda-Osip, Kisielewski, BartkowskaSniatkowska, & Rybakowski, 2015; Shiroma et al., 2014).
Lower urinary tract symptoms (LUTS) appear to be a not
infrequent problem in long-term abusers of ketamine,
and include urinary frequency, urge incontinence,
dysuria, urgency, and hematuria (Chu et al., 2008;
Shahani, Streutker, Dickson, & Stewart, 2007). Severe
sequelae have been reported including interstitial cystitis,
papillary necrosis, and irreversible renal failure. In chronic
pain patients and abusers, LUTS have been reported as
early as five months, although symptoms may begin in
as little as nine days (Chu et al., 2008; Storr & Quibell,
2009; Grégoire, Maclellan, & Finley, 2008). One large
prospective cohort study surveyed 3,806 recreational
users, 1,285 of whom had used ketamine in the year
prior. LUTS was reported in 340 (26.6%) in a dose and
frequency related pattern. Resolution with abstinence
occurred in 51% of cases, and continued deterioration
occurred in 3.8% (Wein, 2013). Mechanisms for these
effects are unknown. In our review, only one complaint
of urinary tract symptoms was found, cystitis, and
judged to be caused not by ketamine, but rather sexual
activity (Diamond et al., 2014). Another setting in which
ketamine’s rapid onset of antidepressant—in addition
to analgesic—effects has been used with success is the
inpatient palliative care setting (Prommer et al., 2012,
Iglewicz et al., 2014), though concern has been raised
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that in the cancer patients, ketamine’s mTor upregulation
could accelerate tumor growth (Yang, Zhou, & Yang,
2011). In treatment of bipolar depression, another
important adverse effect to monitor for is induction of
mania or cycle acceleration. As noted in the Niciu et al.
(2014) review of three larger NIMH trials, this was not
found to be a serious concern, however long-term data in
this area are completely lacking.
Ketamine’s Stereoisomers
Ketamine exists as a racemic mixture of the
S- and R- stereoisomers, yet these appear to have subtly
different effects. S-ketamine has long been known to
have approximately 2-3 times greater potency in terms
of analgesia and anesthesia (Kohrs & Durieux, 1998),
and 3-4 times greater affinity for the PCP binding site
of the NMDA receptor, but only negligible binding to
the sigma receptor. R-ketamine on the other hand, has
greater, although still weak, sigma receptor binding,
but the significance of this is unclear (Vollenweider,
Leenders, Oye, Hell, & Angst, 1997). Observations
from the anesthesia literature initially noted that in
equianalgesic doses, S-ketamine has a lower incidence
of psychotomimetic side effects than either the racemate
or R-stereoisomer (Raeder et al., 2000), leading some
to investigate it for depression. Both the racemate and
S-ketamine appear to have antidepressant effects, but
data regarding psychotomimetic effects of the component
stereoisomers are more contradictory. A separate series
of trials may perhaps explain this; one pilot study of
healthy individuals found that the dose of S-ketamine
required to induce psychosis is 60% of that of the
racemate, suggesting the S-enantiomer is responsible for
such effects (Vollenweider et al., 1997). These authors
found psychotomimetic effects in S-ketamine versus “a
state of relaxation” in R-ketamine (Vollenweider et al.,
1997). Animal studies assessing equimolar equivalents
of each stereoisomer found both to provide a rapid and
long lasting antidepressant effect, but ultimately a longer
durability of effect with the R-enantiomer, leading them
to speculate the R- form may be a good candidate for
future study (Zhang, Li, & Hashimoto, 2014; Hashimoto
et al., 2014). Further research directly comparing S-, R-,
and racemic ketamine is needed to clarify if one indeed
exhibits fewer dissociative effects while still maintaining
antidepressant efficacy.
Further Clinical Issues
There is no uniform definition of treatment
resistance in the literature reviewed, although patients
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with or without treatment resistance, however defined,
respond similarly. In assessing improvements in
depression, the most commonly used measures—the
MADRS and HDRS—may not adequately assess change
over a time scale on the order of hours. Several questions,
for example regarding sleep and appetite, cannot reflect
change over the course of a 40 minute infusion; some
studies have gotten around this by carrying forward
prior subscores (Rasmussen et al., 2013). The issue of
concomitant medications—or their discontinuation—
is another confound which will need to be carefully
managed in the design of future long term studies.
Several potential predictors of response have
received attention. Our review suggests that both
bipolar and unipolar depressed patients may exhibit
short term response to ketamine. Besides the potential
for pharmacologic differences between the S- and Renantiomers discussed above, ketamine is hepatically
metabolized to norketamine, which also has neurotrophic
effects and psychopharmacologic properties. The importance of this is unclear; Sos et al. (2013) found no correlation
between blood levels of ketamine or norketamine and
antidepressant response. Several authors have suggested
that the melancholic subtype of major depression may
augur a greater likelihood of response, but this not been
studied prospectively (Paslakis et al., 2010; Atigari &
Healy, 2013; Gálvez et al., 2014). Multiple studies found
a greater likelihood of antidepressant response in TRD
patients with a family history of alcoholism, compared
to those without, although no relationship to personal
history of alcoholism was seen (Phelps et al., 2009; Niciu
et al., 2014). Ionescu, Luckenbaugh, Niciu, Richards, &
Zarate (2014) found greater response in anxious versus
non-anxious unipolar depression, but in a separate posthoc analysis in bipolar depression found no difference
between the anxious and non-anxious subtypes. At least
in bipolar depression, this is notable because those with
the anxious subtype are frequently poorer responders
to conventional treatment. To this end, in studies of
conditions previously classified as anxiety disorders,
such as post-traumatic stress disorder and obsessivecompulsive disorder, ketamine has also shown benefit
(Feder et al., 2014; Rodriguez et al., 2013).
To date, other agents directed at the
neurochemical system most frequently held to account
for ketamine’s antidepressant effect—NMDA receptor
antagonism—have been disappointing in terms of
extending ketamine’s short-term benefits (Ibrahim et al.,

2012; Mathew et al., 2010; Zarate et al., 2006; HerescoLevy et al., 2006). Additional trials are underway to
explore this strategy, although infusion of a specific
NMDA antagonist, AZD6765, was not effective (Zarate
et al., 2013). Alternative mechanisms, such as ketamine’s
effects on seizure threshold, are worth considering
(Atigari & Healy, 2013).
An obvious question is how dissociative and
antidepressant effects might be related. Our review found
that the time course of these effects differs substantially,
and antidepressant effects can occur in patients who do
not experience even transient dissociative effects and
vice-versa. One post-hoc analysis found that magnitude
of acute dissociative symptoms partially correlated with
later antidepressant response (Luckenbaugh et al., 2014).
Thus, the dissociative effects are not necessarily part of the
antidepressant effects per se. On the other hand, it is worth
considering that this dissociation is part of the unique
effect of ketamine that is not shared by conventional
antidepressants: an altered sense of self that can also lead
to a new state of contentment. This could explain why
recent trials with non-psychoactive NDMA antagonists
have not demonstrated antidepressant efficacy, and may
in fact represent an as yet unexplored aspect of mood
regulation—what might be called the eudaimonic
dimension ( or "well-being," from Aristotle)—that
ketamine has given the field an opening to better explore.
Companion articles in this current issue expand on this
notion in much more depth. It is also worth noting that
nitrous oxide and classic hallucinogens, share similar
dissociative/psychotomimetic
and
antidepressant
effects with ketamine (Nagele et al., 2014; Baumeister,
Barnes, Giaroli, & Tracy, 2014). Similarly, ketamine
and the classic hallucinogens have each been employed
in end of life care, either for depression or anxiety,
but perhaps with a similar mechanism (Iglewicz et
al., 2014; Gasser et al., 2014; Grob et al., 2011). It
may be the case, as with classic hallucinogens, which
were originally termed psychotomimetic, that these
altered states are less “psychotic mimicking” and more
psychedelic, or “mind manifesting.” In the case of classic
hallucinogens, concerns over these effects led their
potential antidepressant benefit to be ignored for many
years (Baumeister et al., 2014).
A corollary issue pertinent to ketamine’s
unique effects is what has been called “set and setting”
(Johnson, Richards, & Griffiths, 2008). That is, the
mind sets of the provider and the patient, and the
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environmental setting in which the treatment session
occurs, may have particularly important impact on
treatment outcome. Consistent with this, two studies
conducted in noisy, crowded, high intensity medical
settings had the poorest outcomes among the studies of
multiple ketamine infusions (Rasmussen et al., 2013;
Diamond et al., 2014). Conversely, recent studies of
MDMA-assisted psychotherapy for post-traumatic stress
disorder (Mithoefer et al., 2013) and psilocybin for end
of life anxiety (Grob et al., 2011) used carefully designed
protocols to optimize these aspects of the interventions.
It is possible that similar optimization of ketamine
treatment would improve antidepressant outcomes.
Several unanswered questions remain in the
clinical use of ketamine for depression. Is the presence of
an anesthesiologist required? By extending the duration
of the ketamine infusion to 100 minutes anesthesiology
monitoring was determined to be unnecessary
(Rasmussen et al., 2013). Another study reports infusions
were performed by a psychiatrist with Basic Life Support
training and code team backup (Zigman & Blier,
2013). A further question, as alluded to in discussion of
alternate routes, is whether ketamine could be used in an
office-based setting: the RCT using intranasal ketamine
amended their protocol after demonstrated safety,
and began discharging individuals four hours after
receiving their doses (Lapidus et al., 2014). Furthermore,
several case reports utilizing IM and other methods of
administration describe successful long-term treatment
in an office-based setting. Ultimately, more rigorous
studies in such settings are needed.
Ketamine has not yet been formally promoted
for general clinical use but has seen growing use among
psychiatrists in private practice and academic centers.
Providers hoping to utilize ketamine for treatment of
depression should take care to offer full informed consent
as well as communicate that this use is off-label from
FDA approved indications of ketamine. There is a relative
paucity of data on both the effectiveness and safety in the
outpatient setting, though case reports suggest this can
successfully be done. Existence of an abuse population
must also be considered when expanding ketamine use
to this setting. Further, there are serious safety concerns
from the abuse and pain management literature, as noted
above. Our review provides strong suggestive support
for the use of more “user friendly” alternatives to IV
infusion, but caution is warranted.
Recommendations for future research
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Based on this review, the following specific
recommendations stand out:
1) Trials to further assess if benefit seen in TRD
extends to non-treatment refractory depression.
2) Direct comparisons between various routes of
administration, both in acute and maintenance
treatment, as well as to both placebo or standard
agents.
4)   Trials to specifically assess anti-suicidal effects,
in both acute and maintenance treatment.
5)   Dose-response relationships for each route of
administration, including monitoring of levels
of both ketamine and norketamine levels.
6) Examination of optimal dosing frequencies for
all routes of administration, with the goal of
extending duration of response
7) Systematic monitoring of psychotomimetic and
dissociative effects with long-term treatment,
and correlations with responses to treatment,
including whether tachyphylaxis to these effects
may occur.
8) Systematic monitoring of neuropsychological
functions, urinary tract related symptoms,
suicidal behavior, and at least in bipolar subjects,
mood switching, during long term treatment.
9) Careful analysis of ketamine’s “eudaimonic” effects
as they relate to antidepressant, dissociative,
psychotomimetic, and antisuicidality effects.
10) Additional trials to follow-up on the suggested
benefits of ketamine in other disorders such as
PTSD and OCD; and as a transpersonal agent
for those with life threatening illness and at the
end-of life.
Conclusion
thorough review of the literature utilizing ketamine
for treatment refractory depression reveals rapid
onset of action in the first several hours, often lasting
several days to a week, after a single infusion. We
acknowledge a common criticism raised about the
limited time frame of efficacy from a single dose of
ketamine, however this does not distinguish it from any
other treatment of depression, including psychotherapy,
medication, or ECT. Furthermore, multiple dosing
studies and alternate routes of administration have
safely and successfully extended the antidepressant
benefit of ketamine, with select cases demonstrating
maintenance for nearly a year. These findings are all
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the more impressive when viewed from the perspective
of an already treatment-resistant population. While
the existing paradigm of 40 minute IV infusions has
proven limitedly effective, much less resource intensive
protocols such as intranasal, intramuscular, oral, and
subcutaneous methods of administration represent a
potential revolution in the use of ketamine. These routes
of administration have the advantage of expanding
ketamine research to the outpatient setting. We did not
find evidence of serious neurocognitive adverse effects in
clinical use, in contrast to what has been reported with
ketamine abuse. This is an area in which ketamine may
distinguish itself from ECT as an alternative for TRD.
Similarly, we did not find evidence of LUTS, but this
has not been systematically investigated. The frequency
and seriousness of LUTS in the abuse population makes
it an important adverse effect to monitor in future long
term studies.Dissociative effects are common, time
limited, generally well tolerated, and appear to subside
in intensity with repeat dosing. These and other unique
effects, distinguish it from currently used monoaminergic
antidepressants and warrant further study in terms of
their ability to advance understanding of depression and
its treatment. Significant hemodynamic effects requiring
intervention are possible but uncommon, and do require
careful monitoring. Potential contraindications do exist,
including psychosis, abuse liability, and hemodynamic
instability, but with care in patient selection unwanted
outcomes can be minimized. Ketamine is clearly a very
promising agent. While we must urge caution in wide
spread clinical application before further research is
completed, our review of the risks and benefits supports
its use in carefully selected cases who have not benefited
from other treatments.
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unipolar

unipolar

2011

2013

Denk et al.

Segmiller et
al.
[2]

yes

yes

yes

6

1

2

N

?

F

1M
1F

?

56

51,
58

Age

unclear

none

1) nicotine
dependence,
2) none

Comorbidities

HTN

continued
S-ketamine

S-ketamine

0.25mg/kg 6
over 40 min

0.25mg/kg 1
over 40 min

100 minutes

2 weeks

2 weeks

HDRS

HDRS

HDRS

yes; though after
1st, 3/6 (50%), and
3rd, 4/6 (68%), infusions

yes, remission
immediately
after infusion

no; 0/2 (0%), though
had near-response

yes; 1/2 (50%)

not reported

n/a

n/a

3 days

Duration of M e a - Depression
re- Durability of benstudy
sure
sponse within 24 efit
hours

1-2x/wk for 4 4 weeks
wks

n/a

weekly

0.25mg/kg 1
over 40 min

S-ketamine

unclear

weekly

0.5mg/kg 1
over 40 min

racemic

Frequency

continued

No. of
doses

Dose

M e d i c a t i o n FormuStatus
lation

																		

[1] Two subjects received 0.5mg/kg racemic ketamine and 0.25mg/kg S-ketamine over 40 minutes in this open-label crossover study.		
[2] Some data not available.																

unipolar

2009

Paul et al. [1]

Diagnosis

Year

Study

Supplemental Table 1. Cases with IV administration of ketamine, Part 1. S-ketamine
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2014

2014

Aligeti et al

Lai et al. [2]

unipolar

bipolar II

unipolar

unipolar
and
bipolar II

unipolar

unipolar

yes

no

yes

yes

no

yes

yes

yes

unipolar

unipolar

yes

yes

yes

unipolar

unipolar

unipolar

yes

yes

unipolar

unipolar

yes

yes

TRD

unipolar

unipolar

Diagnosis

4

1

4

3

3

1

1

2

2

1

1

1

2

2

1

N

2M
2F

M

3M
1F

?

3M

F

F

M

M

M

F

M

M

F

F

Gender

51

32

72

?

1931

37

45

45

50

50

47

55

33

39

47

Age

1) - 3) melancholic
depression

alcohol dependence

1) GAD, parkinsons,
dementia 2) GAD,
dementia, 3) GAD

1) panic disorder,
2) none, 3) bulimia,
bipolar II, cluster C

none

prior pituitary adenoma
resection, B12 deficiency, and hypothyroidism

none

history of alcohol
abuse, hypertension

obesity, sleep apnea

metastatic prostate
cancer

none

alcohol, benzodiazepine, and nicotine
dependence

none

none

schizo-affective
disorder

Comorbidities

continued

off

continued

continued

off

continued

off

unclear

unclear

methylphenidate held day of
infusion

unclear

ativan
continued, off
antidepressants
for 1 week

continued

continued

off for 1 day

Medication
Status

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

racemic

Formulation

0.1mg/kg over
2-5 min
0.2mg/kg over
205 min
0.3mg/kg over
2-5 min
0.4mg/kg over
2-5 min

saline

0.5mg/kg IV
push

0.5mg/kg over
40 min

0.5mg/kg over
40 min

0.5mg/kg over
3 min

0.5mg/kg over
40 min

0.5mg/kg over
40min

0.5mg/kg over
40 min
0.5mg/kg over
40 min

0.5mg/kg over
60min

0.5mg/kg over
40 min

0.5mg/kg over
50min

0.3mg/kg/hr
for 5 days

0.27mg/kg/hr
for 5 days

0.5mg/kg
bolus (for ECT
induction)

Dose

1

1

2-6

16 - 31

1

1

6

2

6

2

2

2

3

1

2

No. of
doses

weekly

once

unclear

varied, from
every other
day to every 2
months

once

once

three times a
week

every other
day
weekly

10 days later

2 wks later

35 days later

2.5 and 7.5
months later

n/a

every 48
hours

Frequency

5 weeks

6 months

unclear

12 months

120 minutes

1 month

12 months

12 days

12 days

13 days

6 months

14 days, 7
days

8 months

6 months

5 days

Duration of
study

MADRS

HDRS7,
MADRS

MADRS

MADRS

group
mean
MADRS

custom
scale

MADRS

BDI

BDI

HDRS,
BDI

HDRS

HDRS

HDRS

HDRS

custom
scale

Measure

1-3 days
n/a
n/a
1 day

no, 0/4 (0%)
no, 0/4 (0%)
yes, 1/4 (25%)

n/a

through 5 days,
unclear afterwards

n/a

12 months in one
patient

n/a

mood remained
improved for 8 days

remission over 3
months via QIDS-SR

relapse at 18 days

relapse at 29 days

6 hrs each time

4 days

1st infusion maintained for 14 days,
2nd infusion
maintained 1 day

"several weeks"

12+ months

5 days

Durability of benefit

yes, 2/4 (50%)

no, 0/4 (0%)

yes

no

yes; though after 2nd,
3rd, or 10th infusions

yes; halved at 120min

yes, dysphoria from
10/10 to 3/10 at 40min

yes, remission within
24 hrs

no, only after 2nd
infusion
yes, after 1st infusion

no, near-response
within first 6 hrs

yes, remission within
24 hours after each
infusion

no; 1st infusion,
response at 48hrs; 2nd
infusion near response
at 48hrs

no; remission via first
HDRS time point at
5 days
no; remission via first
HDRS time point at
5 days

yes; mood rating
improved from 2/10
to 7/10

Depression response
within 24 hours

[1] Includes follow-up publication on the same patient.
[2] Subjects received ascending doses of ketamine, from 0.1 - 0.4mg/kg, interspersed with a saline treatment. Patients were blinded to the order.							

2014

Szymkowicz
et al.

2011

Murrough et al.

2013

2010

Messer et al.

Szymkowicz
et al.

2008

StefanczykSapieha et al.

2013

2008

Kollmar et al.

Yang et al.

2007,
2009

Liebrenz et al
[1]

2013

2006

Correll and
Futter

Zigman and
Blier

2005

Year

Ostroff et al.

Study

Supplemental Table 1. Cases with IV administration of ketamine, Part 2. Racemic ketamine
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(Continued below)

2013

2011

Valentine
et al.

Murrough
et al.

2006

Zarate
et al.

2013

2000

Berman
et al.

Sos et al.

Year

Study

parallel
group

double
blind
crossover

single
blind
crossover

double
blind
crossover

double
blind
crossover

Design

unipolar

unipolar

unipolar

unipolar

unipolar(8)
bipolar(1)

Diagnosis

y

n

n

y

n

TRD

47/25

27

10

18

9

N

35M
37F

15M
15F

4M
6F

16M
12F

4M
5F

Gender

47/43

43

42

47

37

Age

Significantly greater
dissociation
at 40min

not
reported

Significantly greater
dissociation
at 20min;
non-significant by
60min

not
reported

not
reported

CADSS,
ket vs.
PBO

No significant
difference
in BPRS or
BPRS positive
scale

BPRS score
change did
not achieve
statistical
significance
as a covariate
(p=0.10)

Non-significant greater
BPRS positive
symptom
scores at
20minutes to
80minutes.

Significantly
greater BPRS
positive symptoms subscale
scores
compared to
placebo, only
at 40 min

Significantly
greater BPRS
scores.
Non-significant by 80
min. Resolved
at 110min

BPRS, ket
vs. PBO

Mean
YMRS <1
for both
groups
at 40min
(only data
available).

not
reported

not
reported

YMRS
scores
higher at
40 min
only

not
reported

YMRS,
ket vs.
PBO

Supplemental Table 2. Random controlled trials adverse effects

Unipolar Depression
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Elevated blood
pressure, mean of
19 systolic and 9.1
diastolic, resolved at
240min. Midazolam
decreased mean
blood pressure.
Hypotension in one
patient.

"mild" increases
in BP

Significantly elevated
SBP at 10-95 min
mean, peak 40min of
14.1+/-13.4mmHG.
Trend toward
increased DBP. No
effect on heart rate

"elevations
in blood pressure,"

not reported

Hemodynamic,
Respiratory, EKG;
more common with
ketamine

Day of infusion: A) occurring
in > 10% of patients: Nausea/
vomiting, dry mouth, dizziness,
palpitations, sweating, headache,
poor coordination, tremor,
blurred vision, poor concentration, restlessness, anxiety,
decreased energy, and fatigue. B)
Considered distressing in > 10%:
Dizziness, blurred vision, and
poor concentration. Day 1-7 after
infusion: A) Nausea/vomiting,
diarrhea, dizziness on standing,
perspiration, dry skin, rash, dizziness, headache, blurred vision,
poor concentration, restlessness,
anxiety, fatigue, and malaise. B)
Considered distressing in > 10%:
Poor concentration, restlessness,
anxiety, decreased energy, and
fatigue.
Day 1-7 after infusion: A) Nausea/vomiting, diarrhea, dizziness
on standing, perspiration, dry
skin, rash, dizziness, headache,
blurred vision, poor concentra-

"Typical effects" dissociation/perceptual disturbances, confusion,
emotional blunting, euphoria. All
resolved at 60 min.

not reported

perceptual disturbances, confusion, euphoria, dizziness, and
increased libido. The majority of
adverse effects ceased within 80
min after the infusion. Reports of
derealization or depersonalization
ceased by 110min.

not reported

Subjective adverse effects
more common with ketamine

Day of Infusion:
A) Occurring at >
10% incidence:
General malaise
B) Considered
distressing in
> 10%: Poor
coordination.
Day 1-7 after
infusion: A) Palpitations and decreased energy.
B) Considered
distressing in >
10%: General
malaise and
fatigue .
Day 1-7 after
infusion: A) Palpitations and decreased energy.
B) Considered
distressing in >
10%: General
malaise and
fatigue .

worsening
depression

not reported

Gastrointestinal distress,
increased thirst,
headache, metallic taste, and
constipation

not reported

Subjective
adverse effects
more common
in placebo

Ketamine
(2): Hypertension
unresponsive to
beta-blockers.
Hypotension and
bradycardia.

Worsening
depression
in two
receiving
only KET

Elevated
blood
pressure
during
placebo
infusion

none
reported

none
reported

Adverse
event
leading to
discontinuation

Two serious adverse events
during study. Hypotension
and bradycardia during
venipuncture considered
vasovagal, resolved. Suicide
attempt during washout
period prior to administration
of ketamine or midazolam.

BPRS scores were
significantly correlated with
change in MADRS score at
day 7 (P=0.04), and trended
toward significance at days
1 and 4 (p=0.06 and <0.07,
respectively).

-

A) Inverse relationship
trend noted between the
percentage change in HDRS
score at day 1 and the peak
percentage change in BPRS
positive symptoms subscale
score. B) "No serious
adverse events occurred
during the study."

Changes in BPRS or VAShigh scores did not correlate
with percent decreases
observed in HDRS scores

Miscellaneous

Ketamine for Depression

2013

Murrough
et al.

2010

Diazgrandos
et al.

2012

2014

Lai et al.

Zarate
et al.

2014

2013

Lapidus
et al.

Ghasemi
et al.

Design

double
blind
crossover

double
blind
crossover

single
blind
crossover

double
blind
crossover

parallel
group

(Continued from above)

Year

Study

bipolar I
and II

bipolar I
and II

unipolar

unipolar

unipolar

Diagnosis

y

y

y

y

y

TRD

15

18

4

20

9/9

N

6M
12F

2M
2F

10M
10F

8M
10F

Gender

47

48

51

48

38

Age

Significantly greater
dissociation at
40min

not
reported

unclear

"small
increases at
40 minutes"
in KET
group

not reported

CADSS,
ket vs.
PBO

No significant
difference
in BPRS or
BPRS positive subscale
noted.

not reported

unclear

"small
increases at
40 minutes" in
KET group

not reported

BPRS, ket vs.
PBO

Non-significant
lower
YMRS
score

not
reported

unclear

not
reported
(though
in study
design)

not
reported

YMRS,
ket vs.
PBO

Tachycardia in
one patient

Tachycardia and
increased blood
pressure. Resolved
minutes after
infusion.

unclear

Mean increase of 7.6
in SBP. 3 pts > 130
SBP. No pts >100
DBP. No pts over
110 BPM

Non-significant
change in either
group. Non-significant elevation in
SBP and HR in three
ketamine patient on
2nd and 3rd administration, transient.

Hemodynamic,
Respiratory, EKG;
more common with
ketamine

Supplemental Table 2 (cont'd). Random controlled trials adverse effects
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Dry mouth, headache, breast
pain/swelling, leg cramp, dizziness or faintness, difficulty falling
asleep, decrease body temp,
flatulance, concentration difficulty,
drowsy/sleepiness, woozy,
loopy, early morning awkening,
interrupted sleep, vivid dreams,
difficulty speaking, skin irritation,
sweating, noise sensitivity, fearfulness, cough, increased thirst,
diarrhea, increaed appetite, stool
discoloration, increased libido,
tremor and menstrual irregularity.

Adverse events associated
only with ketamine (≥10% of
subjects) included dissociation;
feeling strange, weird, or
bizarre; dry mouth

dose related increase in psychotimimetic side effects.

In > 1 patient: Feeling strange
or unreal (8/18). Poor memory.
Weakness/fatigue. Dizziness.
Poor concentration. Decreased
sexual arousal/orgasm/interest.
Poor coordination. Numbness/
tingling. All resolved by 240
minutes.

not
reported

tion, restlessness, anxiety,
fatigue, and malaise. B)
Considered distressing in > 10%:
Poor concentration, restlessness,
anxiety, decreased energy, and
fatigue.

Subjective adverse effects
more common with ketamine

Irritability,
muscle, bone,
or joint pain,
increased body
temp, "slowed",
and decreased
libido.

unclear

n/a

Trouble sleeping
at 240 minutes
and 240minutes
to 24 hrs post.
At 240 min to
24hrs, sleep
disturbance/
nightmares and
"overall" adverse
effect.

not
reported

Subjective
adverse effects
more common
in placebo

none
reported

Ketamine
(4);
anxiety,
three with
worsening
mood (one
worsening
suicidal
ideation).
Placebo
(1): Hypomania

none

None. 2
withdrew
prior to any
treatment.

not
reported

Adverse
event
leading to
discontinuation

A) "No serious adverse
events occurred during
the study." B)No adverse
event was significantly
different from placebo at
80 min or thereafter.

A) "No serious adverse
events occurred during
the study." B) No
adverse event was
significantly different from
placebo at 80 min or
thereafter.

dose dependent increase in
psychotimimetic side effects

Among subjects who
responded to ketamine, the
increase in CADSS score at
+40 min was 1.75 +/- 4.17
compared with 1.09 +/- 1.76
in subjects who did not
respond to ketamine.

not
reported

Miscellaneous
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15
8 unique
(?)
26
(16M/10F)

10
0 unique
(5M/5F)

yes

yes

yes

yes

Salvadore
et al. 2009
(unipolar)

Diazgranados
et al. 2010
(unipolar)

Salvadore
et al. 2010
(unipolar)
Mathew et al.
2010 (unipolar)

yes

Ibrahim et al.
2011 (unipolar)
Salvadore
et al. 2012
(unipolar)

42
(24M/18F)
14
11 unique
(9M/5F)

14
(7M/7F)

26
(14M/12F)

50

47

Significantly increased at 40
minutes, normal by 80 minutes
not reported

not reported

Significantly increased at 40
minutes, normal by 2 hours

51

31

not reported

not reported

51

48

Inadequate inter-rater reliability

46

not reported

not reported

48

44

Those with positive family
history of alcohol (FHP) had
significantly higher scores at
40minutes compared to group
with family history negative
(FHN).

not reported

CADSS Results

44

44

Age

not reported

not reported

no significant elevation at first
time point of 40min

Nonsignificant mean increase,
baseline at 2 hours.

Nonsignificant changes in
positive symptoms at 240
minutes

Significant decrease in positive
subscale after 230 minutes

Inadequate inter-rater reliability

Significant decrease in
psychotic symptoms after 230
minutes.

not reported

not reported

no significant
elevation at first time
point of 40min

not reported

not reported

not reported

mild positive psychotomimetic
symptoms in two patients,
resolving within 40 min; mild
unpleasant dissociative symptoms in two patients, resolving
within 30 min
not reported

Elevated blood pressure during
infusion (mean 19.8 +/- 10.9
systolic mmHg, 13.4 +/- 7.7 diastolic mmHg) and pulse (mean
10.9 +/- 11.9 bpm). Baseline at
40-80 minutes.

"significant main
effect of time" on
item 1. No effect of
pretreatment.

"A) Tachycardia and
hypertension reported in two
patients, resolved 5minutes
after infusion. B) Bradycardia
in one patient on initial and
repeat infusions, resolved by
2hrs. C) Asymptomatic, mild
hypotension (80/55) developed
in one patient with baseline of
107/48, lasting until discharge
at 24hours, and on two repeat
infusions. D) Asymptomatic
premature ventricular contractions reported in one patient
on repeat infusions 4 and 5,
resolved at 2hrs. E) Bradypnea
noted in one patient on several
infusions and one time"
not reported

Most common: blurry vision,
diminished mental/sharpness,
dizzy/faint, drowsy/sleepy, feeling strange/unreal, headache,
numbness/tingling, ringing
in ears/trouble hearing, and
slurred speech.
6

not reported

not reported

not reported

Mild perceptual disturbances
were observed in most
patients only in the first hour
after infusion.
not reported

not reported

not reported

not reported

not reported

Subjective Adverse Effects

not reported

not reported

not reported

not reported

not reported

not reported

not reported

not reported

Positive symptoms elevated
in FHP and FHN groups at
40 minutes. Baseline by 80
minutes. FHP had significantly
fewer dysphoric symptoms at
120 and 230 minutes.
not reported

not reported

Hemodynamic, Respiratory
and EKG Effects

not reported

YMRS Results

not reported

BPRS Results

"There were no
serious adverse
events, and no
treatment-emergent mania or
suicidality"
12 months

none reported

three times a week

not reported

none noted

none

not reported

not reported

n/a

"No serious
adverse events
occurred during
the study"
not reported

none reported

none reported

not reported

not reported

not reported

not reported

Miscellaneous

none reported

none reported

none reported

none reported

Adverse Event Leading
to Ending Treatment

																		

[1] 6 infusions total, 3x/wk for 2 wks

yes

no

Larkin and
Beautrais 2011
(unipolar)

aan het Rot
et al. 2010
(unipolar)
[1]

33
(20M/13F)

yes

Price et al.
2009 (unipolar)

yes

26
0 unique
(16M/10F)
11
(7M/4F)

yes

Phelps et al.
2009 (unipolar)

23
(14M/9F)

yes

Machado-Vieira et
al. 2009 (unipolar)

N
(gender)

TRD

Supplemental Table 3. Open label investigations adverse effects

Study & Year
(diagnosis)
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yes

yes

yes

Thakurta et al.
2012 (unipolar)

Rybakowski
et al. 2013
(bipolar,
unspecified)

Rasmussen
et al. 2013
(unipolar and
biploar)
[3]

14
(14M)

24
14 unique
(15M/9F)

10
(4M/6F)

25
(4M/21F)

22
(10M/12F)

42
2 unique
(26M/16F)

20
0 unique
(15M/5F)

27
(13M/14F)

N
(gender)

54

48

47

49

50

47

46

49

Age

Significant increase from a
mean of 0 before infusion to
8.60±6.49 at the end of the
infusion, returned to baseline
by 120minutes.

Significant increase from a
mean of 0.3 ±0.5 pre-infusion
to 7.8±12.0 at the peak of
the infusion, and baseline by
240minutes.

not reported

not reported

not reported

Significant decrease to 28
days. First measurement post
infusion at 230minutes.

Significantly increased at 40
minutes, not at later intervals

not reported

CADSS Results

Significant increase of positive
symptoms subscale from a
mean of 4.0±0.1 pre-infusion
to 4.5±0.9 at the peak of the
infusion, and baseline by
240minutes.

No significant change in positive subscale or total BPRS
noted at 2hours or one day.

not reported

Significant decrease in
psychotic symptoms after 230
minutes.

No significant improvement
in positive symptoms found
after multiple comparison
adjustments.

Significant decrease in positive subscale at 80minutes,
120minutes and 230minutes.

Significant increase in positive
subscale at 40minutes only.

BPRS Results

Elevated mood
measured by the
YMRS-1, baseline
by 240minutes.

Isolated symptoms.
No mania.

not reported

not reported

Non-specific
improvement in all
ketamine patients
after day 1.

not reported

not reported

YMRS Results

Elevated blood pressure and/or
heart rate (33%).

No clinically significant elevation in blood pressure during
the infusions. No arrhythmia.
No patients required respiratory
support.

not reported

not reported

Elevations in blood pressure
and pulse, resolved within
80min. No clinically meaningful
EKG changes. No clinically
meaningful changes in respiratory effects.

not reported

Non-specific elevation of blood
pressure reported

Hemodynamic, Respiratory
and EKG Effects

Significant increase in positive
not reported
Elevation from normotensive to
subscale from a mean of
hypertensive blood pressure in
4.0±0 before infusion to
one patient (180/92) that rapidly
4.6±1.9 at the end of the
responded to 10mg labetalol.
infusion, returned to a mean by
No arrhythmia. No patients
120 minutes.
required respiratory support.
[1] 6 infusions total, 3x/wk for 2wks; 									
[2] Reported over 28 days and compared between post treatment with riluzole or placebo. 				
[3] up to 4 infusions total, 2x/wk for 2 wks or until remission. 


yes

yes

Ibrahim et al.
2012 (unipolar)
[2]

Shiroma et a.
2014 (unipolar)
[1]

yes

Cornwell et al.
2012 (unipolar)

yes

yes

Thakurta et al.
2012 (unipolar)

Murrough et al.
2013 (unipolar)
[1]

TRD

Study & Year
(diagnosis)

Supplemental Table 3 (cont'd). Open label investigations adverse effects

"Patient with gastroesophageal
reflux disease had nausea and

The most common effects
were reported with prevalence:
58.3% of patients reported
feeling unreal/strange. 54.2%
reported abnormal sensations,
50% blurred vision, 45.8%
reported feeling drowsy/sleepy.
Largely resolved prior to
subsequent infusions.

Of 10 patients: Vertigo reported by one, dizziness by three,
visual hallucinations by one,
drowsiness by three, dysmegalopsia/anxiety and diplopia by
one, and no adverse effects
reported by three.

not reported

not reported

Generally reported: perceptual
disturbances, drowsiness, confusion, and dizziness occurred
during infusion, resolved within
80min.

not reported

Generally reported: elevated
blood pressure, euphoria,
headache,increased thirst, and
dizziness occurring with ketamine administration ceased
within 60 minutes.

Subjective Adverse Effects

none

Maximum blood pressure
180/115 during infusion.
Unsatisfactory response to
anti-hypertensives. Stabilized upon discontinuation.

none reported

none reported

none reported

none reported

none reported

none reported

Adverse Event Leading to
Ending Treatment

all well enough
to return home
at 4hrs

16.7% reported
that any side
effect impaired
functioning at
any time. No
serious adverse
events occurred
during the
study,There was
no trend towards
increasing
dissociative or
psychotomimetic
effects over the
course of the
trial.

not reported

not reported

not reported

not reported

Referred to Ibrahim et al. 2012

"No serious
adverse events
occurred during
the study"

Miscellaneous
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yes

yes

28
(16M/12F)

47

32

42

36

37

Age

not reported

not reported

not reported

not reported

not reported

CADSS Results

protocol mentioned BPRS,
no result

not reported

not reported

not reported

not reported

BPRS Results

not reported

not reported

not reported

not reported

not reported

YMRS Results

One patient withdrew during
their first treatment due to a
panic attack nine minutes into
the infusion, experiencing
tachycardia and tachypnoea.
One patient was withdrawn due
to concurrent upper respiratory
tract infection. One participant
had a 10 minute vasovagal episode (bp 77/47, pulse 45 bpm,
reduced level of consciousness) 11 minutes into his first
infusion, resolved by 1 hour.

no change in mean SBP or
DBP for all pts combined.
Max 160 SBP, max 90

No change in mean SBP or
DBP for all pts combined.
Max 160 SBP, max 90

No change in mean SBP or
DBP for all pts combined.
Max 160 SBP, max 90
No change in mean SBP or
DBP for all pts combined.
Max 160 SBP, max 90

Hemodynamic, Respiratory
and EKG Effects

"Most patients" reported some
transient effects, including
perceptual

sedation/drowsy 33%

sedation/drowsy 22%,
lightness of body 22%
heavy head 11%

sedation/drowsy 22%,
heavy head 11%

Subjective Adverse Effects

none reported

none

none

none

Adverse Event Leading
to Ending Treatment

"No serious
adverse events
occurred during
the study"

alll well enough
to return home
at 4 hrs

all well enough
to return home
at 4 hrs

all well enough
to return home
at 24 hrs

Miscellaneous

																		

Diamond et al.
2014 (unipolar
and bipolar)

9
(3M/6F)
[ 0.5mg/
kg IV]
9
(2M/7F)
[ 0.5mg/
kg IM ]
9
(1M/8F)
[ 0.25mg/
kg IM ]

yes

yes

27 (9/9/9)

yes

Chilukuri et al.
2014 (unipolar)

N
(gender)
[dose]

TRD

Supplemental Table 3 (cont'd). Open label investigations adverse effects

Study & Year
(diagnosis)

